Endothelial to Mesenchymal Transition (EndoMT) in the pathogenesis of human fibrotic diseases

Journal of Clinical Medicine

Volumn 5, Issue 4, 2016, Pages

  Piera Velazquez, Sonsoles ^a   Mendoza, Fabian A ^a   Jimenez, Sergio A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Collagen; EndoMT; Endothelial cell; Endothelial mesenchymal transition; Extracellular matrix; Fibrosis; Fibrotic diseases; Idiopathic pulmonary fibrosis; Myofibroblast; Systemic sclerosis; Transforming growth factor

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BLEOMYCIN; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CAVEOLIN 1; CD31 ANTIGEN; CD34 ANTIBODY; CONNECTIVE TISSUE GROWTH FACTOR; ENDOTHELIN 1; FIBRILLAR COLLAGEN; FIBRONECTIN; IMATINIB; IMMUNOGLOBULIN G4; INTERLEUKIN 1; ISOPRENALINE; MATRIX METALLOPROTEINASE; METALLOPROTEINASE; MICRORNA; NOTCH RECEPTOR; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; ROTTLERIN; SONIC HEDGEHOG PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR ENDOTHELIAL CADHERIN; VON WILLEBRAND FACTOR;

ANIMAL MODEL; CHAGAS DISEASE; COLLAGEN DISEASE; DISEASE COURSE; END STAGE RENAL DISEASE; EPITHELIAL MESENCHYMAL TRANSITION; FIBROGENESIS; FIBROSING ALVEOLITIS; FIBROTIC DISEASE; GENE DELETION; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; HEART MUSCLE FIBROSIS; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; INTESTINAL FIBROSIS; KIDNEY FIBROSIS; LIVER FIBROSIS; LUNG FIBROSIS; MACROMOLECULE; MYOFIBROBLAST; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PULMONARY HYPERTENSION; RAT; REVIEW; SCHISTOSOMIASIS; SYSTEMIC SCLEROSIS;

EID: 85114281020     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm5040045     Document Type: Review

References (176)

1. Rockey, D. C.; Bell, P. D.; Hill, J. A. Fibrosis-A common pathway to organ injury and failure. N. Engl. J. Med. 2015, 372, 1138-1149. [PubMed]
2. Rosenbloom, J.; Castro, S. V.; Jimenez, S. A. Fibrotic Diseases: Cellular and Molecular Mechanisms and Novel Therapies. Ann. Int. Med. 2010, 152, 159-166. [PubMed]
3. Wynn, T. A. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J. Clin. Invest. 2007, 117, 524-529. [CrossRef] [PubMed]
4. Varga, J.; Abraham, D. Systemic sclerosis: A prototypic multisystem fibrotic disorder. J. Clin. Invest. 2007, 117, 557-567. [CrossRef] [PubMed]
5. Gabrielli, A.; Avvedimento, E. V.; Krieg, T. Scleroderma. N. Engl. J. Med. 2009, 360, 1989-2003. [CrossRef] [PubMed]
6. Ho, Y. Y.; Lagares, D.; Tager, A. M.; Kapoor, M. Fibrosis-A lethal component of systemic sclerosis. Nat. Rev. Rheumatol. 2014, 10, 390-402. [CrossRef] [PubMed]
7. Cowper, S. E.; Su, L. D.; Bhawan, J.; Robin, H. S.; LeBoit, P. E. Nephrogenic fibrosing dermopathy. Am. J. Dermatopathol. 2001, 23, 383-393. [CrossRef] [PubMed]
8. Mendoza, F. A.; Artlett, C. M.; Sandorfi, N.; Latinis, K.; Piera-Velazquez, S.; Jimenez, S. A. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin. Arthritis Rheum. 2006, 35, 238-249. [CrossRef] [PubMed]
9. White, J. M.; Creamer, D.; Du Vivier, A. W.; Pagliuca, A.; Ho, A. Y.; Devereux, S.; Salisbury, J. R.; Mufti, G. J. Sclerodermatous graft-versus-host disease: Clinical spectrum and therapeutic challenges. Br. J. Dermatol. 2007, 156, 1032-1038. [CrossRef] [PubMed]
10. Stone, J. H.; Zen, Y.; Deshpande, V. IgG4-related disease. N. Engl. J. Med. 2012, 366, 539-551. [CrossRef] [PubMed]
11. Kamisawa, T.; Zen, Y.; Pillai, S.; Stone, J. H. IgG4-related disease. Lancet 2015, 385, 1460-1471. [CrossRef]
12. Ding, N. H.; Li, J. J.; Sun, L. Q. Molecular mechanisms and treatment of radiation-induced lung fibrosis. Curr. Drug Targets 2013, 14, 1347-1356. [CrossRef] [PubMed]
13. Abid, S. H.; Malhotra, V.; Perry, M. C. Radiation-induced and chemotherapy-induced pulmonary injury. Curr. Opin. Oncol. 2001, 13, 242-248. [CrossRef] [PubMed]
14. Leask, A. Getting to the heart of the matter: New insights into cardiac fibrosis. Circ. Res. 2015, 116, 1269-1276. [CrossRef] [PubMed]
15. Spagnolo, P.; Sverzellati, N.; Rossi, G.; Cavazza, A.; Tzouvelekis, A.; Crestani, B.; Vancheri, C. Idiopathic pulmonary fibrosis: An update. Ann. Med. 2015, 47, 15-27. [CrossRef] [PubMed]
16. Bonder, A.; Tapper, E. B.; Afdhal, N. H. Contemporary assessment of hepatic fibrosis. Clin. Liver Dis. 2015, 19, 123-134. [CrossRef] [PubMed]
17. Duffield, J. S. Cellular and molecular mechanisms in kidney fibrosis. J. Clin. Invest. 2014, 124, 2299-2306. [CrossRef] [PubMed]
18. Rimal, B.; Greenberg, A. K.; Rom, W. N. Basic pathogenetic mechanisms in silicosis: Current understanding. Curr. Opin. Pulm. Med. 2005, 11, 169-173. [CrossRef] [PubMed]
19. Manning, C. B.; Vallyathan, V.; Mossman, B. T. Diseases caused by asbestos: Mechanisms of injury and disease development. Int. Immunopharmacol. 2002, 2, 191-200. [CrossRef]
20. Gökmen, M. R.; Cosyns, J. P.; Arlt, V. M.; Stiborová, M.; Phillips, D. H.; Schmeiser, H. H.; Simmonds, M. S.; Cook, H. T.; Vanherweghem, J. L.; Nortier, J. L.; et al. The epidemiology, diagnosis, and management of aristolochic acid nephropathy: A narrative review. Ann. Intern. Med. 2013, 158, 469-477. [CrossRef] [PubMed]
21. Colley, D. G.; Bustinduy, A. L.; Secor, W. E.; King, C. H. Human schistosomiasis. Lancet 2014, 383, 2253-2264. [CrossRef]
22. Cunha-Neto, E.; Chevillard, C. Chagas disease cardiomyopathy: Immunopathology and genetics. Mediat. Inflamm. 2014, 2014, 683230. [CrossRef] [PubMed]
23. Jimenez, S. A.; Hitraya, E.; Varga, J. Pathogenesis of scleroderma. Collagen. Rheum. Dis. Clin. N. Am. 1996, 22, 647-674. [CrossRef]
24. Karsdal, M. A.; Manon-Jensen, T.; Genovese, F.; Kristensen, J.; Nielsen, M. J.; Sand, J. M.; Hansen, N.; Bay-Jensen, A. C.; Bager, C. L.; Krag, A.; et al. Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2015, 308, G807-G830. [CrossRef] [PubMed]
25. Thannickal, V. J.; Henke, C. A.; Horowitz, J. C.; Noble, P. W.; Roman, J.; Sime, P. J.; Zhou, Y.; Wells, R. G.; White, E. S.; Tschumperlin, D. J. Matrix biology of idiopathic pulmonary fibrosis: A workshop report of the National Heart, Lung, and Blood Institute. Am. J. Pathol. 2014, 184, 1643-1651. [CrossRef] [PubMed]
26. Kirk, T. Z.; Mark, M. E.; Chua, C. C.; Chua, B. H.; Mayes, M. D. Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J. Biol. Chem. 1995, 270, 3423-3428. [PubMed]
27. Rosenbloom, J.; Mendoza, F. A.; Jimenez, S. A. Strategies for Antifibrotic Therapies. Biochim. Biophys. Acta Mol. Basis Dis. 2013, 1832, 1088-1103. [CrossRef] [PubMed]
28. Castelino, F. V.; Varga, J. Emerging cellular and molecular targets in fibrosis: Implications for scleroderma pathogenesis and targeted therapy. Curr. Opin. Rheumatol. 2014, 26, 607-614. [CrossRef] [PubMed]
29. Denton, C. P. Systemic sclerosis: From pathogenesis to targeted therapy. Clin. Exp. Rheumatol. 2015, 33 (Suppl. 92), S3-S7. [PubMed]
30. Gabbiani, G. The myofibroblast: A key cell for wound healing and fibrocontractive diseases. Prog. Clin. Biol. Res. 1981, 54, 183-194. [PubMed]
31. Abraham, D. J.; Eckes, B.; Rajkumar, V.; Krieg, T. New developments in fibroblast and myofibroblast biology: Implications for fibrosis and scleroderma. Curr. Rheumatol. Rep. 2007, 9, 136-143. [CrossRef] [PubMed]
32. Gilbane, A. J.; Denton, C. P.; Holmes, A. M. Scleroderma pathogenesis: A pivotal role for fibroblasts as effector cells. Arthritis Res. Ther. 2013, 15, 215. [CrossRef] [PubMed]
33. Kendall, R. T.; Feghali-Bostwick, C. A. Fibroblasts in fibrosis: Novel roles and mediators. Front. Pharmacol. 2014, 5, 123. [CrossRef] [PubMed]
34. Hinz, B.; Phan, S. H.; Thannickal, V. J.; Prunotto, M.; Desmoulière, A.; Varga, J.; De Wever, O.; Mareel, M.; Gabbiani, G. Recent developments in myofibroblast biology: Paradigms for connective tissue remodeling. Am. J. Pathol. 2012, 180, 1340-1355. [CrossRef] [PubMed]
35. Hu, B.; Phan, S. H. Myofibroblasts. Curr. Opin. Rheumatol. 2013, 25, 71-77. [CrossRef] [PubMed]
36. Wells, R. G.; Discher, D. E. Matrix elasticity, cytoskeletal tension, and TGF-beta: The insoluble and soluble meet. Sci. Signal 2008, 1. [CrossRef] [PubMed]
37. Hinz, B. Tissue stiffness, latent TGF-beta1 activation, and mechanical signal transduction: Implications for the pathogenesis and treatment of fibrosis. Curr. Rheumatol. 2009, 11, 120-126. [CrossRef]
38. Hinz, B.; Phan, S. H.; Thannickal, V. J.; Galli, A.; Bochaton-Piallat, M. L.; Gabbiani, G. The myofibroblast: One function, multiple origins. Am. J. Pathol. 2007, 170, 1807-1816. [CrossRef] [PubMed]
39. McAnulty, R. J. Fibroblasts and myofibroblasts: Their source, function and role in disease. Int. J. Biochem. Cell. Biol. 2007, 39, 666-671. [CrossRef] [PubMed]
40. Kis, K.; Liu, X.; Hagood, J. S. Myofibroblast differentiation and survival in fibrotic disease. Expert Rev. Mol. Med. 2011, 23. [CrossRef] [PubMed]
41. Falke, L. L.; Gholizadeh, S.; Goldschmeding, R.; Kok, R. J.; Nguyen, T. Q. Diverse origins of the myofibroblast-implications for kidney fibrosis. Nat. Rev. Nephrol. 2015, 11, 233-244. [CrossRef] [PubMed]
42. Poslethwaite, A. E.; Shigemitsu, H.; Kanagat, S. Cellular origins of fibroblasts: Possible implications for organ fibrosis in systemic sclerosis. Curr. Opin. Rheumatol. 2004, 16, 733-738. [CrossRef]
43. Strieter, R. M.; Keeley, E. C.; Hughes, M. A.; Burdick, M. D.; Mehrad, B. The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of pulmonary fibrosis. J. Leukoc. Biol. 2009, 86, 1111-1118. [CrossRef] [PubMed]
44. Herzog, E. L.; Bucala, R. Fibrocytes in health and disease. Exp. Hematol. 2010, 38, 548-556. [CrossRef] [PubMed]
45. Lamouille, S.; Xu, J.; Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell. Biol. 2014, 15, 178-196. [CrossRef] [PubMed]
46. Humphreys, B. D.; Lin, S. L.; Kobayashi, A.; Hudson, T. E.; Nowlin, B. T.; Bonventre, J. V.; Valerius, M. T.; McMahon, A. P.; Duffield, J. S. Fate tracing reveals the pericyte and not epithelial origin on myofibroblasts in kidney fibrosis. Am. J. Pathol. 2010, 176, 85-97. [CrossRef] [PubMed]
47. Kramann, R.; Schneider, R. K.; DiRocco, D. P.; Machado, F.; Fleig, S.; Bondzie, P. A.; Henderson, J. M.; Ebert, B. L.; Humphreys, B. D. Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell 2015, 16, 51-66. [CrossRef] [PubMed]
48. Karasek, M. A. Does transformation of microvascular endothelial cells into myofibroblasts play a key role in the etiology and pathology of fibrotic disease? Med. Hypotheses 2007, 68, 650-655. [CrossRef] [PubMed]
49. Gitler, A. D.; Lu, M. M.; Jiang, Y. Q.; Epstein, J. A.; Gruber, P. J. Molecular markers of cardiac endocardial cushion development. Dev. Dyn. 2003, 228, 643-650. [CrossRef] [PubMed]
50. Arciniegas, E.; Neves, C. Y.; Carrillo, L. M.; Zambrano, E. A.; Ramírez, R. Endothelial-mesenchymal transition occurs during embryonic pulmonary artery development. Endothelium 2005, 12, 193-200. [CrossRef] [PubMed]
51. Zeisberg, E. M.; Taranavski, O.; Zeisberg, M.; Dorfman, A. L.; McMullen, J. R.; Gustafsson, E.; Chandraker, A.; Yuan, X.; Pu, W. T.; Roberts, A. B.; et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 2007, 13, 952-961. [CrossRef] [PubMed]
52. Goumans, M. J.; van Zonneveld, A. J.; ten Dijke, P. Transforming growth factor β-induced endothelial-to-mesenchymal transition: A switch to cardiac fibrosis? Trends Cardiovasc. Med. 2008, 18, 293-298. [CrossRef] [PubMed]
53. Zeisberg, E. M.; Potenta, S. E.; Sugimoto, H.; Zeisberg, M.; Kalluri, R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J. Am. Soc. Nephrol. 2008, 19, 2282-2287. [CrossRef] [PubMed]
54. Li, J.; Bertram, J. F. Review: Endothelial-Myofibroblast Transition, a new player in diabetic renal fibrosis. Nephrology 2010, 15, 507-512. [CrossRef] [PubMed]
55. Piera-Velazquez, S.; Li, Z.; Jimenez, S. A. Role of Endothelial-Mesenchymal Transition (EndoMT) in the Pathogenesis of Fibrotic Disorders. Am. J. Pathol. 2011, 179, 1074-1084. [CrossRef] [PubMed]
56. Lin, F.; Wang, N.; Zhang, T. C. The role of endothelial-mesenchymal transition in development and pathological process. IUBMB. Life 2012, 64, 717-723. [CrossRef] [PubMed]
57. LeBleu, V. S.; Taduri, G.; O'Connell, J.; Teng, Y.; Cooke, V. G.; Woda, C.; Sugimoto, H.; Kalluri, R. Origin and function of myofibroblasts in kidney fibrosis. Nat. Med. 2012, 19, 1047-1053. [CrossRef] [PubMed]
58. Zeisberg, M.; Kalluri, R. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am. J. Cell. Physiol. 2013, 304, C216-C225. [CrossRef] [PubMed]
59. Rieder, F.; Kessler, S. P.; West, G. A.; Bhilocha, S.; de la Motte, C.; Sadler, T. M.; Gopalan, B.; Stylianou, E.; Fiocchi, C. Inflammation-induced endothelial-to-mesenchymal transition: A novel mechanism of interstitial fibrosis. Am. J. Pathol. 2011, 179, 2660-2673. [CrossRef] [PubMed]
60. Yoshimatsu, Y.; Watabe, T. Roles of TGF-β signals in endothelial-mesenchymal transition during cardiac fibrosis. Int. J. Inflam. 2011, 2011, 724080. [CrossRef] [PubMed]
61. Cooley, B. C.; Nevado, J.; Mellad, J.; Yang, D.; St Hilaire, C.; Negro, A.; Fang, F.; Chen, G.; San, H.; Walts, A. D.; et al. TGF-β signaling mediates endothelial-to mesenchymal transition (EndoMT) during vein graft remodeling. Sci. Transl. Med. 2014, 6, 227ra34. [CrossRef] [PubMed]
62. Kitao, A.; Sato, Y.; Sawada-Kitamura, S.; Harada, K.; Sasaki, M.; Morikawa, H.; Shiomi, S.; Honda, M.; Matsui, O.; Nakanuma, Y. Endothelial to mesenchymal transition via transforming growth factor-beta1/Smad activation is associated with portal venous stenosis in idiopathic portal hypertension. Am. J. Pathol. 2009, 175, 616-626. [CrossRef] [PubMed]
63. Mintet, E.; Rannou, E.; Buard, V.; West, G.; Guipaud, O.; Tarlet, G.; Sabourin, J. C.; Benderitter, M.; Fiocchi, C.; Milliat, F.; et al. Identification of endothelial-to-mesenchymal transition as a potential participant in radiation proctitis. Am. J. Pathol. 2015, 185, 2550-2562. [CrossRef] [PubMed]
64. Mendoza, F.; Piera-Velazquez, S.; Farber, J.; Feghali-Bostwick, C.; Jimenez, S. A. Endothelial cells expressing endothelial and mesenchymal cell gene products in Systemic Sclerosis-associated interstitial lung disease lung tissues. Arthritis Rheum. 2016, 68, 210-217. [CrossRef] [PubMed]
65. Ranchoux, B.; Antigny, F.; Rucker-Martin, C.; Hautefort, A.; Péchoux, C.; Bogaard, H. J.; Dorfmüller, P.; Remy, S.; Lecerf, F.; Planté, S.; et al. Endothelial-to-mesenchymal transition in pulmonary hypertension. Circulation 2015, 131, 1006-1018. [CrossRef] [PubMed]
66. Good, R. B.; Gilbane, A. J.; Trinder, S. L.; Denton, C. P.; Coghlan, G.; Abraham, D. J.; Holmes, A. M. Endothelial to Mesenchymal Transition Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension. Am. J. Pathol. 2015, 185, 1850-1858. [CrossRef] [PubMed]
67. Moore-Morris, T.; Guimarães-Camboa, N.; Banerjee, I.; Zambon, A. C.; Kisseleva, T.; Velayoudon, A.; Stallcup, W. B.; Gu, Y.; Dalton, N. D.; Cedenilla, M.; et al. Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. J. Clin. Invest. 2014, 124, 2921-2934. [CrossRef] [PubMed]
68. Welch-Reardon, K. M.; Wu, N.; Hughes, C. C. A role for partial endothelial-mesenchymal transitions in angiogenesis? Arterioscler. Thromb. Vasc. Biol. 2015, 35, 303-308. [CrossRef] [PubMed]
69. Grande, M. T.; Sánchez-Laorden, B.; López-Blau, C.; De Frutos, C. A.; Boutet, A.; Arévalo, M.; Rowe, R. G.; Weiss, S. J.; López-Novoa, J. M.; Nieto, M. A. Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nat. Med. 2015, 21, 989-997. [CrossRef] [PubMed]
70. Lovisa, S.; LeBleu, V. S.; Tampe, B.; Sugimoto, H.; Vadnagara, K.; Carstens, J. L.; Wu, C. C.; Hagos, Y.; Burckhardt, B. C.; Pentcheva-Hoang, T.; et al. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat. Med. 2015, 21, 998-1009. [CrossRef] [PubMed]
71. Roberts, A. B.; Sporn, M. B.; Assoian, R. K.; Smith, J. M.; Roche, N. S.; Wakefield, L. M.; Heine, U. I.; Liotta, L. A.; Falanga, V.; Kehrl, J. H.; et al. Transforming growth factor type beta: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. PNAS 1986, 83, 4167-4171. [CrossRef] [PubMed]
72. Gonzalez, D. M.; Medici, D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci. Signal 2014, 7. [CrossRef] [PubMed]
73. Border, W. A.; Noble, N. A. Transforming growth factor beta in tissue fibrosis. N. Engl. J. Med. 1994, 331, 1286-1292. [PubMed]
74. Varga, J.; Whitfield, M. L. Transforming growth factor-beta in systemic sclerosis (scleroderma). Front. Biosci. 2009, 1, 226-235. [CrossRef]
75. Jiménez, S. A.; Castro, S. V.; Piera-Velázquez, S. Role of growth factors in the pathogenesis of tissue fibrosis in systemic sclerosis. Curr. Rheumatol. Rev. 2010, 6, 283-294. [CrossRef] [PubMed]
76. Lafyatis, R. Transforming growth factor β-At the centre of systemic sclerosis. Nat. Rev. Rheumatol. 2014, 10, 706-719. [CrossRef] [PubMed]
77. Pohlers, D.; Brenmoehl, J.; Löffler, I.; Müller, C. K.; Leipner, C.; Schultze-Mosgau, S.; Stallmach, A.; Kinne, R. W.; Wolf, G. TGF-beta and fibrosis in different organs-Molecular pathway imprints. Biochim. Biophys. Acta 2009, 1792, 746-756. [CrossRef] [PubMed]
78. Biernacka, A.; Dobaczewski, M.; Frangogiannis, N. G. TGF-β signaling in fibrosis. Growth Factors 2011, 29, 196-202. [CrossRef] [PubMed]
79. Goumans, M. J.; Liu, Z.; ten Dijke, P. TGF-beta signaling in vascular biology and dysfunction. Cell Res. 2009, 19, 116-127. [CrossRef] [PubMed]
80. Medici, D.; Potenta, S.; Kalluri, R. Transforming growth factor-β2 promotes Snail-mediated endothelial mesenchymal transition through convergence of Smad-dependent and Smad-independent signaling. Biochem. J. 2011, 433, 515-520. [CrossRef] [PubMed]
81. Van Meeteren, L. A.; ten Dijke, P. Regulation of endothelial cell plasticity by TGF-β. Cell Tissue Res. 2012, 347, 177-186. [CrossRef] [PubMed]
82. Vandewalle, C.; Van Roy, F.; Berx, G. The role of the ZEB family of transcription factors in development and disease. Cell Mol. Life Sci. 2009, 66, 773-787. [CrossRef] [PubMed]
83. Piera-Velazquez, S.; Jimenez, S. A. Molecular mechanisms of endothelial to mesenchymal cell transition (EndoMT) in experimentally induced fibrotic diseases. Fibrogenesis Tissue Repair 2012, 5 (Suppl. 1), S7.
84. Li, Z.; Jimenez, S. A. Protein kinase Cδ and c-Abl kinase are required for transforming growth factor β induction of endothelial-mesenchymal transition in vitro. Arthritis Rheum. 2011, 63, 2473-2483. [CrossRef] [PubMed]
85. Xavier, S.; Vasko, R.; Matsumoto, K.; Zullo, J. A.; Chen, R.; Maizel, J.; Chander, P. N.; Goligorsky, M. S. Curtailing endothelial TGF-β signaling is sufficient to reduce endothelial-mesenchymal transition and fibrosis in CKD. J. Am. Soc. Nephrol. 2015, 26, 817-829. [CrossRef] [PubMed]
86. Shi, S.; Srivastava, S. P.; Kanasaki, M.; He, J.; Kitada, M.; Nagai, T.; Takagi, S.; Kanasaki, K.; Koya, D. Interactions of DPP-4 and integrin β1 influences endothelial-to mesenchymal transition. Kidney Int. 2015, 88, 479-489. [CrossRef] [PubMed]
87. Louvi, A.; Artavanis-Tsakonas, S. Notch and disease: A growing field. Semin. Cell. Dev. Biol. 2012, 23, 473-480. [CrossRef] [PubMed]
88. Kugler, M. C.; Joyner, A. L.; Loomis, C. A.; Munger, J. S. Sonic hedgehog signaling in the lung. From development to disease. Am. J. Respir. Cell Mol. Biol. 2015, 52, 1-13. [CrossRef] [PubMed]
89. Distler, A.; Lang, V.; Del Vecchio, T.; Huang, J.; Zhang, Y.; Beyer, C.; Lin, N. Y.; Palumbo-Zerr, K.; Distler, O.; Schett, G.; et al. Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability. Ann. Rheum. Dis. 2014, 73, 1264-1268. [CrossRef] [PubMed]
90. Noseda, M.; McLean, G.; Niessen, K.; Chang, L.; Pollet, I.; Montpetit, R.; Shahidi, R.; Dorovini-Zis, K.; Li, L.; Beckstead, B.; et al. Notch activation results in phenotypic and functional changes consistent with endothelial-to-mesenchymal transformation. Circ. Res. 2004, 94, 910-917. [CrossRef] [PubMed]
91. Niessen, K.; Fu, Y.; Chang, L.; Hoodless, P. A.; McFadden, D.; Karsan, A. Slug is a direct Notch target required for initiation of cardiac cushion cellularization. J. Cell Biol. 2008, 182, 315-325. [CrossRef] [PubMed]
92. Chang, A. C.; Fu, Y.; Garside, V. C.; Niessen, K.; Chang, L.; Fuller, M.; Setiadi, A.; Smrz, J.; Kyle, A.; Minchinton, A.; et al. Notch initiates the endothelial-to-mesenchymal transition in the atrioventricular canal through autocrine activation of soluble guanylyl cyclase. Dev. Cell 2011, 21, 288-300. [CrossRef] [PubMed]
93. Fu, Y.; Chang, A.; Chang, L.; Niessen, K.; Eapen, S.; Setiadi, A.; Karsan, A. Differential regulation of transforming growth factor beta signaling pathways by Notch in human endothelial cells. J. Biol. Chem. 2009, 284, 19452-19462. [CrossRef] [PubMed]
94. Ding, H.; Zhou, D.; Hao, S.; Zhou, L.; He, W.; Nie, J.; Hou, F. F.; Liu, Y. Sonic Hedgehog Signaling Mediates Epithelial-Mesenchymal Communication and Promotes Renal Fibrosis. J. Am. Soc. Nephrol. 2012, 23, 801-813. [CrossRef] [PubMed]
95. Syn, W. K.; Jung, Y.; Omenetti, A.; Abdelmalek, M.; Guy, C. D.; Yang, L.; Wang, J.; Witek, R. P.; Fearing, C. M.; Pereira, T. A.; et al. Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology 2009, 137, 1478-1488. [CrossRef] [PubMed]
96. Fabian, S. L.; Penchev, R. R.; Jacques, B. S.; Rao, A. N.; Sipilä, P.; West, K. A.; McMahon, A. P.; Humphreys, B. D. Hedgehog-Gli Pathway Activation during Kidney Fibrosis. Am. J. Pathol. 2012, 180, 2935-2951. [CrossRef] [PubMed]
97. Bolaños, A. L.; Milla, C. M.; Lira, J. C.; Ramírez, R.; Checa, M.; Barrera, L.; García-Alvarez, J.; Carbajal, V.; Becerril, C.; Gaxiola, M.; et al. Role of Sonic Hedgehog in idiopathic pulmonary fibrosis. Am. J. Physiol. Cell Mol. Physiol. 2012, 303, L978-L990. [CrossRef] [PubMed]
98. Horn, A.; Palumbo, K.; Cordazzo, C.; Dees, C.; Akhmetshina, A.; Tomcik, M.; Zerr, P.; Avouac, J.; Gusinde, J.; Zwerina, J.; et al. Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis Rheum. 2012, 64, 2724-2733. [CrossRef] [PubMed]
99. Clevers, H.; Nusse, R. Wnt/β-catenin signaling and disease. Cell 2012, 149, 1192-1205. [CrossRef] [PubMed]
100. Niehrs, C. The complex world of WNT receptor signaling. Nat. Rev. Mol. Cell Biol. 2012, 13, 767-779. [CrossRef] [PubMed]
101. Bergmann, C.; Distler, J. H. Canonical Wnt signaling in systemic sclerosis. Lab. Invest. 2016. [CrossRef] [PubMed]
102. Wei, J.; Fang, F.; Lam, A. P.; Sargent, J. L.; Hamburg, E.; Hinchcliff, M. E.; Gottardi, C. J.; Atit, R.; Whitfield, M. L.; Varga, J. Wnt/β-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum. 2012, 64, 2734-2745. [CrossRef] [PubMed]
103. Beyer, C.; Schramm, A.; Akhmetshina, A.; Dees, C.; Kireva, T.; Gelse, K.; Sonnylal, S.; de Crombrugghe, B.; Taketo, M. M.; Distler, O.; et al. β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Ann. Rheum. Dis. 2012, 71, 761-767. [CrossRef] [PubMed]
104. Lam, A. P.; Flozak, A. S.; Russell, S.; Wei, J.; Jain, M.; Mutlu, G. M.; Budinger, G. R.; Feghali-Bostwick, C. A.; Varga, J.; Gottardi, C. J. Nuclear β-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation. Am. J. Respir. Cell Mol. Biol. 2011, 45, 915-922. [CrossRef] [PubMed]
105. Aisagbonhi, O.; Rai, M.; Ryzhov, S.; Atria, N.; Feoktistov, I.; Hatzopoulos, A. K. Experimental myocardial infarction triggers canonical Wnt signaling and endothelial-to-mesenchymal transition. Dis. Model. Mech. 2011, 4, 469-483. [CrossRef] [PubMed]
106. Li, L.; Chen, L.; Zang, J.; Tang, X.; Liu, Y.; Zhang, J.; Bai, L.; Yin, Q.; Lu, Y.; Cheng, J.; et al. C3a and C5a receptor antagonists ameliorate endothelial-myofibroblast transition via the Wnt/β-catenin signaling pathway in diabetic kidney disease. Metabolism 2015, 64, 597-610. [CrossRef] [PubMed]
107. Cheng, S. L.; Shao, J. S.; Behrmann, A.; Krchma, K.; Towler, D. A. Dkk1 and MSX2-Wnt7b signaling reciprocally regulate the endothelial-mesenchymal transition in aortic endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 1679-1689. [CrossRef] [PubMed]
108. Razani, B.; Zhang, X. L.; Bitzer, M.; von Gersdorff, G.; Böttinger, E. P.; Lisanti, M. P. Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. J. Biol. Chem. 2001, 276, 6727-6738. [CrossRef] [PubMed]
109. Del Galdo, F.; Lisanti, M. P.; Jimenez, S. A. Caveolin-1, transforming growth factor-beta receptor internalization, and the pathogenesis of systemic sclerosis. Curr. Opin. Rheumatol. 2008, 20, 713-719. [CrossRef] [PubMed]
110. Gvaramia, D.; Blaauboer, M. E.; Hanemaaijer, R.; Everts, V. Role of caveolin-1 in fibrotic diseases. Matrix Biol. 2013, 32, 307-315. [CrossRef] [PubMed]
111. Del Galdo, F.; Sotgia, F.; de Almeida, C. J.; Jasmin, J. F.; Musick, M.; Lisanti, M. P.; Jiménez, S. A. Decreased expression of caveolin 1 in patients with systemic sclerosis: Crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum. 2008, 58, 2854-2865. [CrossRef] [PubMed]
112. Wang, X. M.; Zhang, Y.; Kim, H. P.; Zhou, Z.; Feghali-Bostwick, C. A.; Liu, F.; Ifedigbo, E.; Xu, X.; Oury, T. D.; Kaminski, N.; et al. Caveolin-1: A critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J. Exp. Med. 2006, 203, 2895-2906. [CrossRef] [PubMed]
113. Tourkina, E.; Richard, M.; Gööz, P.; Bonner, M.; Pannu, J.; Harley, R.; Bernatchez, P. N.; Sessa, W. C.; Silver, R. M.; Hoffman, S. Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 294, L843-L861. [CrossRef] [PubMed]
114. Jasmin, J. F.; Mercier, I.; Dupuis, J.; Tanowitz, H. B.; Lisanti, M. P. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. Circulation 2006, 114, 912-920. [CrossRef] [PubMed]
115. Li, Z.; Wermuth, P. J.; Benn, B. S.; Lisanti, M. P.; Jimenez, S. A. Caveolin-1 deficiency induces spontaneous endothelial-to-mesenchymal transition in murine pulmonary endothelial cells in vitro. Am. J. Pathol. 2013, 182, 325-331. [CrossRef] [PubMed]
116. Shi-Wen, X.; Denton, C. P.; Dashwood, M. R.; Holmes, A. M.; Bou-Gharios, G.; Pearson, J. D.; Black, C. M.; Abraham, D. J. Fibroblast matrix gene expression and connective tissue remodeling: Role of endothelin-1. J. Invest. Dermatol. 2001, 116, 417-425. [CrossRef] [PubMed]
117. Jing, J.; Dou, T. T.; Yang, J. Q.; Chen, X. B.; Cao, H. L.; Min, M.; Cai, S. Q.; Zheng, M.; Man, X. Y. Role of endothelin-1 in the skin fibrosis of systemic sclerosis. Eur. Cytokine Netw. 2015, 26, 10-14. [PubMed]
118. Widyantoro, B.; Emoto, N.; Nakayama, K.; Anggrahini, D. W.; Adiarto, S.; Iwasa, N.; Yagi, K.; Miyagawa, K.; Rikitake, Y.; Suzuki, T.; et al. Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. Circulation 2010, 121, 2407-2418. [CrossRef] [PubMed]
119. Wermuth, P.; Li, Z.; Jimenez, S. A. Synergistic stimulation of Transforming Growth Factor-β1 induced endothelial-to-mesenchymal transition and tissue fibrosis by Endothelin-1 (ET-1): A novel profibrotic effect of ET-1. 2016. under review.
120. Cipriani, P.; Di Benedetto, P.; Ruscitti, P.; Capece, D.; Zazzeroni, F.; Liakouli, V.; Pantano, I.; Berardicurti, O.; Carubbi, F.; Pecetti, G.; et al. The endothelial-mesenchymal transition in systemic sclerosis is induced by endothelin-1 and transforming growth factor-β and may be blocked by macitentan, a dual endothelin-1 receptor antagonist. J. Rheumatol. 2015, 42, 1808-1816. [CrossRef] [PubMed]
121. Semenza, G. L. Hypoxia-inducible factors in physiology and medicine. Cell 2012, 148, 399-408. [CrossRef] [PubMed]
122. Lokmic, Z.; Musyoka, J.; Hewitson, T. D.; Darby, I. A. Hypoxia and hypoxia signaling in tissue repair and fibrosis. Int. Rev. Cell Mol. Biol. 2012, 296, 139-185. [PubMed]
123. Hasse, V. H. Pathophysiological consequences of HIF activation; HIF as a modulator of fibrosis. Ann. N. Y. Acad. Sci. 2009, 1177, 57-65. [CrossRef] [PubMed]
124. Beyer, C.; Schett, G.; Gay, S.; Distler, O.; Distler, J. H. Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Res. Ther. 2009, 11, 220. [CrossRef] [PubMed]
125. Distler, J. H.; Jüngel, A.; Pileckyte, M.; Zwerina, J.; Michel, B. A.; Gay, R. E.; Kowal-Bielecka, O.; Matucci-Cerinic, M.; Schett, G.; Marti, H. H.; et al. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum. 2007, 56, 4203-4215. [CrossRef] [PubMed]
126. Sánchez-Elsner, T.; Botella, L. M.; Velasco, B.; Corbí, A.; Attisano, L.; Bernabéu, C. Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J. Biol. Chem. 2001, 276, 38527-38535. [CrossRef] [PubMed]
127. Higgins, D. F.; Kimura, K.; Bernhardt, W. M.; Shrimanker, N.; Akai, Y.; Hohenstein, B.; Saito, Y.; Johnson, R. S.; Kretzler, M.; Cohen, C. D.; et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J. Clin. Invest. 2007, 117, 3810-3820. [CrossRef] [PubMed]
128. Xu, X.; Tan, X.; Tampe, B.; Sanchez, E.; Zeisberg, M.; Zeisberg, E. M. Snail is a direct target of hypoxia-inducible factor 1α (HIF1α) in hypoxia-induced endothelial to mesenchymal transition of human coronary endothelial cells. J. Biol. Chem. 2015, 290, 16653-16664. [CrossRef] [PubMed]
129. Choi, S. H.; Hong, Z. Y.; Nam, J. K.; Lee, H. J.; Jang, J.; Yoo, R. J.; Lee, Y. J.; Lee, C. Y.; Kim, K. H.; Park, S.; et al. A Hypoxia-induced vascular endothelial-to-mesenchymal transition in development of radiation-induced pulmonary fibrosis. Clin. Cancer Res. 2015, 21, 3716-3726. [CrossRef] [PubMed]
130. Liu, R. M.; Desai, L. P. Reciprocal regulation of TGF-β and reactive oxygen species: A perverse cycle for fibrosis. Redox. Biol. 2015, 6, 565-577. [CrossRef] [PubMed]
131. Richter, K.; Konzack, A.; Pihlajaniemi, T.; Heljasvaara, R.; Kietzmann, T. Redox-fibrosis: Impact of TGFβ1 on ROS generators, mediators and functional consequences. Redox. Biol. 2015, 6, 344-352. [CrossRef] [PubMed]
132. Bourji, K.; Meyer, A.; Chatelus, E.; Pincemail, J.; Pigatto, E.; Defraigne, J. O.; Singh, F.; Charlier, C.; Geny, B.; Gottenberg, J. E.; et al. High reactive oxygen species in fibrotic and nonfibrotic skin of patients with diffuse cutaneous systemic sclerosis. Free Radic. Biol. Med. 2015, 87, 282-289. [CrossRef] [PubMed]
133. Kliment, C. R.; Oury, T. D. Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis. Free Radic. Biol. Med. 2010, 49, 707-717. [CrossRef] [PubMed]
134. Siani, A.; Tirelli, N. Myofibroblast differentiation: Main features, biomedical relevance, and the role of reactive oxygen species. Antioxid. Redox. Signal 2014, 21, 768-785. [CrossRef] [PubMed]
135. Barnes, J. L.; Gorin, Y. Myofibroblast differentiation during fibrosis: Role of NAD(P)H oxidases. Kidney Int. 2011, 79, 944-956. [CrossRef] [PubMed]
136. Jiang, F.; Liu, G. S.; Dusting, G. J.; Chan, E. C. NADPH oxidase-dependent redox signaling in TGF-β-mediated fibrotic responses. Redox. Biol. 2014, 2, 267-272. [CrossRef] [PubMed]
137. Amara, N.; Goven, D.; Prost, F.; Muloway, R.; Crestani, B.; Boczkowski, J. NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts. Thorax 2010, 65, 733-738. [CrossRef] [PubMed]
138. Hecker, L.; Vittal, R.; Jones, T.; Jagirdar, R.; Luckhardt, T. R.; Horowitz, J. C.; Pennathur, S.; Martinez, F. J.; Thannickal, V. J. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat. Med. 2009, 15, 1077-1081. [CrossRef] [PubMed]
139. Cucoranu, I.; Clempus, R.; Dikalova, A.; Phelan, P. J.; Ariyan, S.; Dikalov, S.; Sorescu, D. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ. Res. 2005, 97, 900-907. [CrossRef] [PubMed]
140. Crestani, B.; Besnard, V.; Boczkowski, J. Signalling pathways from NADPH oxidase-4 to idiopathic pulmonary fibrosis. Int. J. Biochem. Cell Biol. 2011, 43, 1086-1089. [CrossRef] [PubMed]
141. Sancho, P.; Mainez, J.; Crosas-Molist, E.; Roncero, C.; Fernández-Rodriguez, C. M.; Pinedo, F.; Huber, H.; Eferl, R.; Mikulits, W.; Fabregat, I. NADPH oxidase NOX4 mediates stellate cell activation and hepatocyte cell death during liver fibrosis development. PLoS ONE 2012, 7, e45285. [CrossRef] [PubMed]
142. Paik, Y. H.; Kim, J.; Aoyama, T.; De Minicis, S.; Bataller, R.; Brenner, D. A. Role of NADPH oxidases in liver fibrosis. Antioxid. Redox Signal 2014, 20, 2854-2872. [CrossRef] [PubMed]
143. Spadoni, T.; Svegliati Baroni, S.; Amico, D.; Albani, L.; Moroncini, G.; Avvedimento, E. V.; Gabrielli, A. A reactive oxygen species-mediated loop maintains increased expression of NADPH oxidases 2 and 4 in skin fibroblasts from patients with systemic sclerosis. Arthritis Rheumatol. 2015, 67, 1611-1622. [CrossRef] [PubMed]
144. Piera-Velazquez, S.; Makul, A.; Jimenez, S. A. Increased expression of NADPH Oxidase 4 (NOX4) in Systemic Sclerosis dermal fibroblasts: Regulation of Transforming Growth Factor β. Arthritis Rheumatol. 2015, 67, 2749-2758. [CrossRef] [PubMed]
145. Wang, Y.; Stricker, H. M.; Gou, D.; Liu, L. miRNA: Past and present. Front. Biosci. 2007, 12, 2316-2329. [CrossRef] [PubMed]
146. Jiang, X.; Tsitsiou, E.; Herrick, S. E.; Lindsay, M. A. MicroRNAs and the regulation of fibrosis. FEBS J. 2010, 277, 2015-2021. [CrossRef] [PubMed]
147. Rutnam, Z. J.; Wight, T. N.; Yang, B. miRNAs regulate expression and function of extracellular matrix molecules. Matrix Biol. 2013, 32, 74-85. [CrossRef] [PubMed]
148. Bowen, T.; Jenkins, R. H.; Fraser, D. J. MicroRNAs, transforming growth factor beta-1, and tissue fibrosis. J. Pathol. 2013, 229, 274-285. [CrossRef] [PubMed]
149. Babalola, O.; Mamalis, A.; Lev-Tov, H.; Jagdeo, J. The role of microRNAs in skin fibrosis. Arch. Dermatol. Res. 2013, 305, 763-776. [CrossRef] [PubMed]
150. Zhu, H.; Luo, H.; Zuo, X. MicroRNAs: Their involvement in fibrosis pathogenesis and use as diagnostic biomarkers in scleroderma. Exp. Mol. Med. 2013, 45, e41. [CrossRef] [PubMed]
151. Pandit, K. V.; Milosevic, J. MicroRNA regulatory networks in idiopathic pulmonary fibrosis. Biochem. Cell Biol. 2015, 93, 129-137. [CrossRef] [PubMed]
152. Thum, T. Noncoding RNAs and myocardial fibrosis. Nat. Rev. Cardiol. 2014, 11, 655-663. [CrossRef] [PubMed]
153. He, Y.; Huang, C.; Zhang, S. P.; Sun, X.; Long, X. R.; Li, J. The potential of microRNAs in liver fibrosis. Cell Signal 2012, 24, 2268-2272. [CrossRef] [PubMed]
154. Srivastava, S. P.; Koya, D.; Kanasaki, K. MicroRNAs in kidney fibrosis and diabetic nephropathy: Roles on EMT and EndMT. Biomed. Res. Int. 2013, 2013, 125469. [CrossRef] [PubMed]
155. Ghosh, A. K.; Nagpal, V.; Covington, J. W.; Michaels, M. A.; Vaughan, D. E. Molecular basis of cardiac endothelial-to-mesenchymal transition (EndMT): Differential expression of microRNAs during EndMT. Cell Signal 2012, 24, 1031-1036. [CrossRef] [PubMed]
156. Nagpal, V.; Rai, R.; Place, A. T.; Murphy, S. B.; Verma, S. K.; Ghosh, A. K.; Vaughan, D. E. MiR-125b is critical for fibroblast0to-myofibroblast transition and cardiac fibrosis. Circulation 2016, 133, 291-301. [PubMed]
157. Zhang, J.; Zhang, Z.; Zhang, D. Y.; Zhu, J.; Zhang, T.; Wang, C. microRNA 126 inhibits the transition of endothelial progenitor cells to mesenchymal cells via the PIK3R2-PI3K/Akt signalling pathway. PLoS ONE 2013, 8, e83294. [CrossRef] [PubMed]
158. Kumarswamy, R.; Volkmann, I.; Jazbutyte, V.; Dangwal, S.; Park, D. H.; Thum, T. Transforming growth factor-β-induced endothelial-to-mesenchymal transition is partly mediated by microRNA-21. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 361-369. [CrossRef] [PubMed]
159. Guo, Y.; Li, P.; Bledsoe, G.; Yang, Z. R.; Chao, L.; Chao, J. Kallistatin inhibits TGF-β-induced endothelial-mesenchymal transition by differential regulation of microRNA-21 and eNOS expression. Exp. Cell Res. 2015, 337, 103-110. [CrossRef] [PubMed]
160. Kumar, S.; Kim, C. W.; Simmons, R. D.; Jo, H. Role of flow-sensitive microRNAs in endothelial dysfunction and atherosclerosis: Mechanosensitive athero-miRs. Arterioscler. Thromb. Vasc. Biol. 2014, 34, 2206-2216. [CrossRef] [PubMed]
161. Katsura, A.; Suzuki, H. I.; Ueno, T.; Mihira, H.; Yamazaki, T.; Yasuda, T.; Watabe, T.; Mano, H.; Yamada, Y.; Miyazono, K. MicroRNA-31 is a positive modulator of endothelial-mesenchymal transition and associated secretory phenotype induced by TGF-β. Genes Cells 2016, 21, 99-116. [CrossRef] [PubMed]
162. Chen, P. Y.; Qin, L.; Barnes, C.; Charisse, K.; Yi, T.; Zhang, X.; Ali, R.; Medina, P. P.; Yu, J.; Slack, F. J.; et al. FGF regulates TGF-β signaling and endothelial-to mesenchymal transition via control of let-7 miRNA expression. Cell Rep. 2012, 2, 1684-1696. [CrossRef] [PubMed]
163. Nagai, T.; Kanasaki, M.; Srivastava, S. P.; Nakamura, Y.; Ishigaki, Y.; Kitada, M.; Shi, S.; Kanasaki, K.; Koya, D. N-acetyl-seryl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-mesenchymal transition. Biomed. Res. Int. 2014, 2014, 696475. [CrossRef] [PubMed]
164. Kanasaki, K.; Shi, S.; Kanasaki, M.; He, J.; Nagai, T.; Nakamura, Y.; Ishigaki, Y.; Kitada, M.; Srivastava, S. P.; Koya, D. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes 2014, 63, 2120-2131. [CrossRef] [PubMed]
165. Zhou, X.; Chen, X.; Cai, J. J.; Chen, L. Z.; Gong, Y. S.; Wang, L. X.; Gao, Z.; Zhang, H. Q.; Huang, W. J.; Zhou, H. Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway. Drug Des. Devel. Ther. 2015, 9, 4599-4611. [CrossRef] [PubMed]
166. Li, J.; Qu, X.; Bertram, J. F. Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am. J. Pathol. 2009, 175, 1380-1388. [CrossRef] [PubMed]
167. He, J.; Xu, Y.; Koya, D.; Kanasaki, K. Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease. Clin. Exp. Nephrol. 2013, 17, 488-497. [CrossRef] [PubMed]
168. Hashimoto, N.; Phan, S. H.; Imaizumi, K.; Matsuo, M.; Nakashima, H.; Kawabe, T.; Shimokata, K.; Hasegawa, Y. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2010, 43, 161-172. [CrossRef] [PubMed]
169. Chrobak, I.; Lenna, S.; Stawski, L.; Trojanowska, M. Interferonpromotes vascular remodeling in human microvascular endothelial cells by upregulating endothelin (ET)-1 and transforming growth factor (TGF) β2. J. Cell Physiol. 2013, 228, 1774-1783. [CrossRef] [PubMed]
170. Xu, X.; Tan, X.; Tampe, B.; Nyamsuren, G.; Liu, X.; Maier, L. S.; Sossalla, S.; Kalluri, R.; Zeisberg, M.; Hasenfuss, G.; et al. Epigenetic balance of aberrant Rasal1 promoter methylation and hydroxymethylation regulates cardiac fibrosis. Cardiovasc. Res. 2015, 105, 279-291. [CrossRef] [PubMed]
171. Charytan, D. M.; Padera, R.; Helfand, A. M.; Zeisberg, M.; Xu, X.; Liu, X.; Himmelfarb, J.; Cinelli, A.; Kalluri, R.; Zeisberg, E. M. Increased concentration of circulating angiogenesis and nitric oxide inhibitors induces endothelial to mesenchymal transition and myocardial fibrosis in patients with chronic kidney disease. Int. J. Cardiol. 2014, 176, 99-109. [CrossRef] [PubMed]
172. Arciniegas, E.; Frid, M. G.; Douglas, I. S.; Stenmark, K. R. Perspectives on endothelial-to-mesenchymal transition: Potential contribution to vascular remodeling in chronic pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 2007, 293, L1-L8. [CrossRef] [PubMed]
173. Jimenez, S. A. Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis. ISRN. Rheumatol. 2013, 2013, 835948. [CrossRef] [PubMed]
174. Sadler, T.; Scarpa, M.; Rieder, F.; West, G.; Stylianou, E. Cytokine-induced chromatin modifications of the type I collagen alpha 2 gene during intestinal endothelial-to-mesenchymal transition. Inflamm. Bowel Dis. 2013, 19, 1354-1364. [CrossRef] [PubMed]
175. Jimenez, S. A.; Piera-Velazquez, S. Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality? Matrix Biol. 2016. [CrossRef] [PubMed]
176. Sanchez-Duffhues, G.; Orlova, V.; Ten Dijke, P. In Brief: Endothelial-to-mesenchymal transition. J. Pathol. 2016, 238, 378-380. [CrossRef] [PubMed]